- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02417844
Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
April 15, 2020 updated by: Boehringer Ingelheim
Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions
Two tamsulosin HClformulations will be tested in fed state
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion criteria:
Health male volunteers 18 years and older
Exclusion criteria:
History of hypersensitivity or allergy to IMP or its excipients or any related medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tamsulosin
|
|
Active Comparator: Tamsulosin HCl
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Measured Concentration (Cmax)
Time Frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Maximum measured concentration of analyte in plasma (Cmax)
|
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Area Under the Concentration-time Curve From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)
Time Frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
|
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Area Under the Concentration-time Curve From 0 Extrapolated to Infinity (AUC0-inf)
Time Frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).
|
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Maximum Plasma Concentration (Tmax)
Time Frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Time from last dosing to the maximum plasma concentration (tmax).
|
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Terminal Elimination Rate Constant (λz)
Time Frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Terminal elimination rate constant in plasma (λz)
|
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Apparent Terminal Elimination Half-life (t1/2)
Time Frame: Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Apparent terminal elimination half-life of the analyte in plasma (t1/2)
|
Before drug administration (0 hours (h)) and 1h, 2h, 3h, 4h, 5h, 6h, 6.5h, 7h, 7.5h, 8h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
April 13, 2015
First Submitted That Met QC Criteria
April 15, 2015
First Posted (Estimate)
April 16, 2015
Study Record Updates
Last Update Posted (Actual)
April 17, 2020
Last Update Submitted That Met QC Criteria
April 15, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Tamsulosin
Other Study ID Numbers
- 527.89
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on Tamsulosin HCL
-
Hanmi Pharmaceutical Company LimitedCompletedBenign Prostate HyperplasiaKorea, Republic of
-
GL Pharm Tech CorporationCompletedBenign Prostatic HyperplasiaKorea, Republic of
-
Lawson Health Research InstituteNot yet recruitingUrinary Retention PostoperativeCanada
-
Boehringer IngelheimCompleted
-
Chong Kun Dang PharmaceuticalCompletedBenign Prostatic HyperplasiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedBenign Prostatic HyperplasiaKorea, Republic of
-
Boehringer IngelheimCompleted
-
Timothy Boone, MD, PhDAstellas Pharma US, Inc.CompletedLower Urinary Tract SymptomsUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedUrologic DiseasesUnited Kingdom